BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25316394)

  • 1. Renal function of cancer patients "fit" for Cisplatin chemotherapy: physician perspective.
    Montoya J; Luna HG; Amparo JR; Casasola C; Cristal-Luna G
    Gulf J Oncolog; 2014 Jul; 1(16):64-72. PubMed ID: 25316394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
    Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
    BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.
    Tsao CK; Moshier E; Seng SM; Godbold J; Grossman S; Winston J; Oh WK; Galsky MD
    Clin Genitourin Cancer; 2012 Mar; 10(1):15-20. PubMed ID: 22130294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
    Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
    BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
    Raj GV; Iasonos A; Herr H; Donat SM
    J Clin Oncol; 2006 Jul; 24(19):3095-100. PubMed ID: 16809735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
    JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
    Merouani A; Davidson SA; Schrier RW
    Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
    Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
    Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of methods for estimating glomerular filtration rate in head and neck cancer patients treated with cisplatin.
    Lindberg L; Brødbæk K; Hägerström EG; Bentzen J; Kristensen B; Zerahn B
    Scand J Clin Lab Invest; 2017 Jul; 77(4):237-246. PubMed ID: 28317454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
    Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
    J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.
    Dahal A; Bellows BK; Sonpavde G; Tantravahi SK; Choueiri TK; Galsky MD; Agarwal N
    Am J Clin Oncol; 2016 Oct; 39(5):497-506. PubMed ID: 24824144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal tolerance to cisplatin in patients 70 years and older.
    Cubillo A; Cornide M; López JL; Molina R; Feliu J; Espinosa E; Zamora P; de Castro J; Ordoñez A; González Barón M
    Am J Clin Oncol; 2001 Apr; 24(2):192-7. PubMed ID: 11319297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine.
    Rashid ST; Salman M; Agarwal S; Hamilton G
    Eur J Vasc Endovasc Surg; 2006 Sep; 32(3):294-9. PubMed ID: 16716614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
    Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
    Dash A; Galsky MD; Vickers AJ; Serio AM; Koppie TM; Dalbagni G; Bochner BH
    Cancer; 2006 Aug; 107(3):506-13. PubMed ID: 16773629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function, concomitant medication use and outcomes following acute coronary syndromes.
    Reddan DN; Szczech L; Bhapkar MV; Moliterno DJ; Califf RM; Ohman EM; Berger PB; Hochman JS; Van de Werf F; Harrington RA; Newby LK
    Nephrol Dial Transplant; 2005 Oct; 20(10):2105-12. PubMed ID: 16030030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of empiric antibiotic dosing in critically ill trauma patients: Are we under-dosing based on augmented renal clearance and inaccurate renal clearance estimates?
    Barletta JF; Mangram AJ; Byrne M; Hollingworth AK; Sucher JF; Ali-Osman FR; Shirah GR; Dzandu JK
    J Trauma Acute Care Surg; 2016 Dec; 81(6):1115-1121. PubMed ID: 27533906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic kidney disease in prevalent orthotopic heart transplant recipients using a new CKD-EPI formula.
    Przybylowski P; Malyszko J; Malyszko J
    Ann Transplant; 2010; 15(1):32-5. PubMed ID: 20305315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.